{"id":"abt-267","safety":{"commonSideEffects":[{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL4761843","moleculeType":"Unknown","molecularWeight":"704.93"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ABT-267 blocks CCR2, a G-protein coupled receptor expressed on monocytes and other immune cells, thereby decreasing their migration to inflamed tissues. This mechanism is intended to reduce inflammatory responses in diseases characterized by excessive monocyte infiltration and activation. The drug was developed to address inflammatory and fibrotic conditions where monocyte-driven inflammation plays a pathogenic role.","oneSentence":"ABT-267 is a selective inhibitor of the chemokine receptor CCR2 that reduces monocyte recruitment to sites of inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:58:36.769Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Diabetic kidney disease"},{"name":"Liver fibrosis / NASH (non-alcoholic steatohepatitis)"}]},"trialDetails":[{"nctId":"NCT02460133","phase":"PHASE4","title":"Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nova Scotia Health Authority","startDate":"2015-07-10","conditions":"Hepatitis C Virus","enrollment":44},{"nctId":"NCT03003338","phase":"PHASE4","title":"MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2017-10-24","conditions":"Hepatitis C, Chronic","enrollment":5},{"nctId":"NCT02219490","phase":"PHASE3","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-10-30","conditions":"Chronic Hepatitis C Virus (HCV) Infection Genotype 1","enrollment":1596},{"nctId":"NCT02634008","phase":"PHASE3","title":"Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2016-06","conditions":"Hepatitis C, Acute","enrollment":83},{"nctId":"NCT02167945","phase":"PHASE3","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-06-12","conditions":"Chronic Hepatitis C Virus (HCV) Infection Genotype 1","enrollment":615},{"nctId":"NCT02333292","phase":"","title":"Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions","status":"COMPLETED","sponsor":"Valme University Hospital","startDate":"2014-12","conditions":"Chronic Hepatitis C Infection","enrollment":1128},{"nctId":"NCT02581020","phase":"","title":"The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-01-14","conditions":"Hepatitis C Virus","enrollment":344},{"nctId":"NCT02786537","phase":"PHASE4","title":"Study of Oral Treatments for Hepatitis C","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-06","conditions":"Chronic Hepatitis C","enrollment":1275},{"nctId":"NCT02194998","phase":"PHASE2","title":"Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-09-16","conditions":"HIV Infections, Hepatitis C","enrollment":46},{"nctId":"NCT02486406","phase":"PHASE2, PHASE3","title":"A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10-28","conditions":"Chronic Hepatitis C Infection","enrollment":64},{"nctId":"NCT02555943","phase":"PHASE2, PHASE3","title":"DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-02","conditions":"Chronic Hepatitis C Infection, HBV Coinfection, Hepatitis B Reactivation","enrollment":23},{"nctId":"NCT01715415","phase":"PHASE3","title":"A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-11","conditions":"Chronic Hepatitis C Infection","enrollment":395},{"nctId":"NCT02247401","phase":"PHASE3","title":"Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-11-04","conditions":"HCV, Hepatitis C Infection, Genotype 4","enrollment":160},{"nctId":"NCT01685203","phase":"PHASE2","title":"A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-08","conditions":"Hepatitis C, Chronic","enrollment":316},{"nctId":"NCT02023112","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-01","conditions":"Hepatitis C Virus","enrollment":171},{"nctId":"NCT02582632","phase":"PHASE3","title":"A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-11-24","conditions":"Hepatitis C Infection, Hepatitis C Virus","enrollment":166},{"nctId":"NCT02707952","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-02-22","conditions":"Chronic Hepatitis C Virus, Hepatitis C Virus","enrollment":295},{"nctId":"NCT01939197","phase":"PHASE2, PHASE3","title":"A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-08-30","conditions":"Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection, Chronic Hepatitis C","enrollment":318},{"nctId":"NCT02219503","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-09","conditions":"Chronic Hepatitis C Infection, Compensated Cirrhosis","enrollment":60},{"nctId":"NCT01716585","phase":"PHASE3","title":"A Study to Evaluate Chronic Hepatitis C Infection","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-11","conditions":"Chronic Hepatitis C Infection","enrollment":636},{"nctId":"NCT01674725","phase":"PHASE3","title":"A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-08","conditions":"Chronic Hepatitis C Infection","enrollment":187},{"nctId":"NCT01767116","phase":"PHASE3","title":"A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-12","conditions":"Chronic Hepatitis C Infection","enrollment":419},{"nctId":"NCT01995071","phase":"PHASE2","title":"A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-11","conditions":"Chronic Hepatitis C, Hepatitis C Virus, Compensated Cirrhosis","enrollment":89},{"nctId":"NCT01704755","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-10","conditions":"Chronic Hepatitis C Infection, Compensated Cirrhosis","enrollment":381},{"nctId":"NCT01833533","phase":"PHASE3","title":"A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-03","conditions":"Chronic Hepatitis C Infection","enrollment":305},{"nctId":"NCT02292719","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-12-19","conditions":"Chronic Hepatitis C Virus Infection","enrollment":70},{"nctId":"NCT04952207","phase":"","title":"Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C","status":"UNKNOWN","sponsor":"Qing XIe","startDate":"2019-03-06","conditions":"Hepatitis C, Chronic","enrollment":300},{"nctId":"NCT02461745","phase":"PHASE4","title":"Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2015-06","conditions":"Hepatitis C, Chronic","enrollment":200},{"nctId":"NCT04662138","phase":"","title":"Safety and Efficacy of Different Antiviral Regimens for Hepatitis C Virus Relapse","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2020-08-24","conditions":"Hepatitis C, Relapse, Antivirals","enrollment":100},{"nctId":"NCT03201718","phase":"","title":"A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-08-17","conditions":"Hepatitis C Virus (HCV)","enrollment":505},{"nctId":"NCT02945228","phase":"","title":"Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotype 2","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-10-26","conditions":"Chronic Hepatitis C Virus","enrollment":449},{"nctId":"NCT04391985","phase":"PHASE1, PHASE2","title":"Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2017-03-01","conditions":"Chronic Hepatitis C Virus Infection","enrollment":113},{"nctId":"NCT04378608","phase":"PHASE1, PHASE2","title":"Ombitasvir /Paritaprevir/Ritonavir Plus Ribavirin on HCV GT4","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2017-01-05","conditions":"Hepatitis C Virus Infection","enrollment":100},{"nctId":"NCT02629172","phase":"","title":"Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-01-05","conditions":"Chronic Hepatitis C Virus","enrollment":3043},{"nctId":"NCT03499639","phase":"PHASE4","title":"Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney Disease","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-05-01","conditions":"End-stage Renal Disease, HCV Coinfection","enrollment":110},{"nctId":"NCT02609659","phase":"PHASE3","title":"Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10-28","conditions":"Hepatitis C Virus (HCV)","enrollment":105},{"nctId":"NCT03002818","phase":"","title":"Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-01","conditions":"Chronic Hepatitis C Virus (HCV)","enrollment":41},{"nctId":"NCT02803138","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-07-07","conditions":"Chronic Hepatitis C","enrollment":256},{"nctId":"NCT02615145","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12-03","conditions":"Chronic Hepatitis C","enrollment":472},{"nctId":"NCT02851069","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Colombia","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-02-23","conditions":"Chronic Hepatitis C","enrollment":66},{"nctId":"NCT02734173","phase":"PHASE4","title":"Pilot HCV Direct Acting Antiviral Therapy and Metabolism","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2015-07","conditions":"Hepatitis C","enrollment":24},{"nctId":"NCT03050905","phase":"PHASE4","title":"Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus Genotype 2K/1B","status":"COMPLETED","sponsor":"HaEmek Medical Center, Israel","startDate":"2017-06-22","conditions":"HCV Coinfection","enrollment":7},{"nctId":"NCT04047680","phase":"","title":"eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-02","conditions":"Hepatitis C, Renal Disease, Viral Hepatitis C","enrollment":441},{"nctId":"NCT03423641","phase":"","title":"An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2011-01-01","conditions":"Hepatitis C, Chronic","enrollment":33808},{"nctId":"NCT02636608","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-11-27","conditions":"Chronic Hepatitis C","enrollment":244},{"nctId":"NCT02874066","phase":"PHASE4","title":"PrOD for Non-Cirrhotic Patients With HCV-1b Receiving Hemodialysis","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2017-03-13","conditions":"Hepatitis Viruses","enrollment":46},{"nctId":"NCT02618928","phase":"","title":"The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in France","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12-15","conditions":"Chronic Hepatitis C","enrollment":735},{"nctId":"NCT02498015","phase":"PHASE4","title":"A Phase IV Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir for Chronic Hepatitis C Genotype 1 Virus Infection","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2016-08","conditions":"Hepatitis C, Chronic","enrollment":87},{"nctId":"NCT02582658","phase":"","title":"Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10-06","conditions":"Chronic Hepatitis C","enrollment":173},{"nctId":"NCT03965286","phase":"","title":"Effect of Direct AntiViral Drugs of Chronic HCV on eGFR in Assuit Universiry Hospital","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-06-01","conditions":"Antiviral Drug","enrollment":80},{"nctId":"NCT02817594","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-01-20","conditions":"Chronic Hepatitis C","enrollment":51},{"nctId":"NCT02581163","phase":"","title":"Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10-07","conditions":"Chronic Hepatitis C, Genotype 1 or 4","enrollment":314},{"nctId":"NCT02582671","phase":"","title":"The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-11-05","conditions":"Chronic Hepatitis C","enrollment":101},{"nctId":"NCT02581189","phase":"","title":"Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10-13","conditions":"Chronic Hepatitis C","enrollment":565},{"nctId":"NCT03887637","phase":"","title":"Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C)","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2019-03-30","conditions":"Chronic Hepatitis C","enrollment":180},{"nctId":"NCT03549832","phase":"NA","title":"Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-01-01","conditions":"HCV Coinfection","enrollment":40},{"nctId":"NCT02725866","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-04-05","conditions":"Chronic Hepatitis C","enrollment":216},{"nctId":"NCT03053180","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-20","conditions":"Chronic Hepatitis C","enrollment":60},{"nctId":"NCT02807402","phase":"","title":"Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Romania","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-07-14","conditions":"Chronic Hepatitis C","enrollment":522},{"nctId":"NCT02798315","phase":"","title":"Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-05-25","conditions":"Chronic Hepatitis C","enrollment":40},{"nctId":"NCT02669940","phase":"","title":"Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-04-15","conditions":"Chronic Hepatitis C, Genotype 1","enrollment":158},{"nctId":"NCT03710252","phase":"PHASE4","title":"A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Study","status":"COMPLETED","sponsor":"American Research Corporation","startDate":"2016-03","conditions":"Chronic Hepatitis C","enrollment":100},{"nctId":"NCT02640547","phase":"","title":"Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-11-26","conditions":"Chronic Hepatitis C","enrollment":394},{"nctId":"NCT02517528","phase":"PHASE3","title":"ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-07-20","conditions":"Chronic Hepatitis C Virus (HCV)","enrollment":104},{"nctId":"NCT01314261","phase":"PHASE2","title":"Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-03","conditions":"Chronic Hepatitis C, Hepatitis C Virus (HCV) Infection","enrollment":37},{"nctId":"NCT01563536","phase":"PHASE2","title":"Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-02","conditions":"Chronic Hepatitis C Infection","enrollment":12},{"nctId":"NCT01609933","phase":"PHASE2","title":"A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-12-18","conditions":"Chronic Hepatitis C","enrollment":32},{"nctId":"NCT02023099","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-12","conditions":"Chronic Hepatitis C Infection","enrollment":363},{"nctId":"NCT01854528","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-06","conditions":"Chronic Hepatitis C Infection","enrollment":148},{"nctId":"NCT01854697","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-03","conditions":"Chronic Hepatitis C Infection","enrollment":311},{"nctId":"NCT01672983","phase":"PHASE2","title":"A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-07","conditions":"Chronic Hepatitis C Infection","enrollment":110},{"nctId":"NCT01911845","phase":"PHASE2","title":"An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-04","conditions":"Chronic Hepatitis C Infection, Chronic Hepatitis C","enrollment":38},{"nctId":"NCT03341988","phase":"PHASE1","title":"Evaluation of Treatment of Chronic HCV Patients in Chronic Kidney Disease Versus End Stage Renal Disease Patients","status":"COMPLETED","sponsor":"Assiut University","startDate":"2017-11-22","conditions":"Hepatitis C","enrollment":100},{"nctId":"NCT02758509","phase":"","title":"Impact of Antiviral Therapy on Gastroesophageal Varices.","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2010-01-01","conditions":"Chronic Hepatitis C, Cirrhosis","enrollment":237},{"nctId":"NCT03122132","phase":"","title":"Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r+Dasabuvir 8 Weeks","status":"COMPLETED","sponsor":"Hepa C","startDate":"2017-02-20","conditions":"Hepatitis C Infection","enrollment":200},{"nctId":"NCT03067883","phase":"PHASE2","title":"Efficacy and Safety of Qurevo Plus Ribavirin Based Therapy for Hepatitis C With or Without Cirrhosis in Haemodialysis Patients","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2016-11-09","conditions":"Chronic Hepatitis c","enrollment":40},{"nctId":"NCT02356562","phase":"PHASE2","title":"A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-02-03","conditions":"Chronic Hepatitis C Infection","enrollment":29},{"nctId":"NCT02504099","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"AbbVie","startDate":"2015-07","conditions":"Chronic Hepatitis C Infection","enrollment":3},{"nctId":"NCT01773070","phase":"PHASE3","title":"A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2013-06","conditions":"Hepatitis C","enrollment":478},{"nctId":"NCT02487199","phase":"PHASE3","title":"Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-09-30","conditions":"Hepatitis C Virus (HCV)","enrollment":18},{"nctId":"NCT02207088","phase":"PHASE3","title":"Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-09-23","conditions":"Chronic Hepatitis C, Hepatitis C Virus, Compensated Cirrhosis","enrollment":68},{"nctId":"NCT01782495","phase":"PHASE2","title":"A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-02-25","conditions":"Chronic Hepatitis C Infection","enrollment":129},{"nctId":"NCT02493855","phase":"PHASE2","title":"Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-06","conditions":"Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1a","enrollment":46},{"nctId":"NCT02517515","phase":"PHASE3","title":"ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-07","conditions":"Hepatitis C Virus (HCV)","enrollment":650},{"nctId":"NCT02442284","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-05-13","conditions":"Chronic Hepatitis C, Cirrhosis, Hepatitis C Virus","enrollment":99},{"nctId":"NCT02476617","phase":"PHASE3","title":"Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-06","conditions":"Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1a","enrollment":25},{"nctId":"NCT03296930","phase":"PHASE4","title":"Effect Of DAAs For Treatment Of HCV On Normal Kidney","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2017-10-01","conditions":"Antiviral Drug Adverse Reaction","enrollment":100},{"nctId":"NCT02446717","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-04","conditions":"Chronic Hepatitis C, Hepatitis C Virus, HCV","enrollment":141},{"nctId":"NCT02265237","phase":"PHASE3","title":"A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-10-28","conditions":"Hepatitis C Virus","enrollment":184},{"nctId":"NCT02442271","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-04-27","conditions":"Chronic Hepatitis C Infection","enrollment":222},{"nctId":"NCT02219477","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-11-24","conditions":"Chronic Hepatitis C, Decompensated Cirrhosis, Hepatitis C Virus","enrollment":36},{"nctId":"NCT03149289","phase":"","title":"Hepatitis C Virus Infection in Patients With Hemoglobinopathies","status":"COMPLETED","sponsor":"Società Italiana Talassemie ed Emoglobinopatie","startDate":"2015-03-01","conditions":"Hepatitis C, Chronic, Hemoglobinopathies","enrollment":168},{"nctId":"NCT03133065","phase":"PHASE4","title":"Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2014-09","conditions":"Liver Transplantation","enrollment":89},{"nctId":"NCT02399345","phase":"PHASE3","title":"Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-03","conditions":"Chronic Hepatitis C Virus (HCV Infection Genotype 1)","enrollment":10},{"nctId":"NCT02806362","phase":"PHASE3","title":"Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD)","status":"WITHDRAWN","sponsor":"AbbVie","startDate":"2016-09","conditions":"Chronic Hepatitis C Virus","enrollment":""},{"nctId":"NCT02950870","phase":"PHASE4","title":"Efficacy Study to Evaluate the Effect of New Antiviral Drugs on HCV Infection.","status":"UNKNOWN","sponsor":"University of Modena and Reggio Emilia","startDate":"2016-12","conditions":"Chronic Hepatitis, C Virus","enrollment":75},{"nctId":"NCT02057003","phase":"","title":"Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients","status":"UNKNOWN","sponsor":"Valme University Hospital","startDate":"2012-01","conditions":"Hepatitis C, Chronic, Human Immunodeficiency Virus","enrollment":1000},{"nctId":"NCT01458535","phase":"PHASE2","title":"A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-09","conditions":"Hepatitis C Virus","enrollment":61},{"nctId":"NCT02216422","phase":"PHASE3","title":"A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-09","conditions":"Chronic Hepatitis C Virus (HCV) Infection","enrollment":36},{"nctId":"NCT02646111","phase":"PHASE3","title":"Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With and Without Ribavirin in Protease-Inhibitors (\"PI\") Failures","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2016-01","conditions":"Hepatitis C","enrollment":120}],"_emaApprovals":[],"_faersSignals":[{"count":14,"reaction":"ANAEMIA"},{"count":14,"reaction":"HYPERBILIRUBINAEMIA"},{"count":10,"reaction":"JAUNDICE"},{"count":7,"reaction":"DIARRHOEA"},{"count":6,"reaction":"DEHYDRATION"},{"count":6,"reaction":"DYSPNOEA"},{"count":5,"reaction":"BLOOD BILIRUBIN INCREASED"},{"count":5,"reaction":"CHEST PAIN"},{"count":5,"reaction":"CONFUSIONAL STATE"},{"count":5,"reaction":"ENCEPHALOPATHY"}],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ombitasvir","Ombitasvir","ABT-267 also known as ombitasvir"],"phase":"phase_3","status":"active","brandName":"ABT-267","genericName":"ABT-267","companyName":"AbbVie (prior sponsor, Abbott)","companyId":"abbvie-prior-sponsor-abbott","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ABT-267 is a selective inhibitor of the chemokine receptor CCR2 that reduces monocyte recruitment to sites of inflammation. Used for Diabetic kidney disease, Liver fibrosis / NASH (non-alcoholic steatohepatitis).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}